Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.
Benign multiple sclerosis (BMS) occurs in about 15% of patients with relapsing-remitting multiple sclerosis (RRMS) that over time do not develop significant neurological disability. The molecular events associated with BMS are not clearly understood. This study sought to underlie the biological mech...
Main Authors: | Anat Achiron, Anna Feldman, David Magalashvili, Mark Dolev, Michael Gurevich |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3470584?pdf=render |
Similar Items
-
Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis
by: Anat Achiron, et al.
Published: (2010-05-01) -
Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
by: Anat Achiron, et al.
Published: (2009-01-01) -
Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine-related Pathways
by: A. Achiron, et al.
Published: (2004-01-01) -
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
by: Anat Achiron, et al.
Published: (2021-04-01) -
Cognitive function in multiple sclerosis: A long-term look on the bright side.
by: Yermi Harel, et al.
Published: (2019-01-01)